Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patient on hemodialysis

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 198-203

  Moist, Louise M ^a   Muirhead, Norm ^a   Wazny, Lori D ^b   Gallo, Kerri L ^c   Heidenheim, A Paul ^c   House, Andrew A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Dosage; Erythropoietin; Hemodialysis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; IRON; VITAMIN D DERIVATIVE; WARFARIN;

ADULT; AGED; ANEMIA; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; ERYTHROCYTE APLASIA; FEMALE; FUNDING; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TERTIARY HEALTH CARE;

AGED; ANEMIA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 33144454609     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G425     Document Type: Article

References (20)

1. Toffelmire E, Barrett BJ, Fenton SS, et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. J Am Soc Nephrol 1999;10(suppl):S287-321.
2. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antiery-thropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
3. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoietin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:439-46.
4. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992;2:1405-16.
5. Paganini EP, Eschbach JW, Lazarus JM, et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis 1995;26:331-40.
6. Parker KP, Mitch WE, Stivelman JC, Macon EJ, Bailey JL, Sands JM. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol 1997;8:288-93.
7. McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis 2001;37:E36.
8. Muirhead N, Churchill DN, Goldstein M, et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 1992:12:303-10.
9. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoietin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998;339:578-83.
10. Tomson CR, Feehally J, Walls J. Crossover comparison of intravenous and subcutaneous erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1992;7:129-32.
11. Horl WH. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous. Acta Haematol 1992;87(suppl 1):16-9.
12. Eidemak I, Friedberg MO, Ladefoged SD, Lokkegaard H, Pedersen E, Skielboe M. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD. Nephrol Dial Transplant 1992;7:526-9.
13. Chang CH, Chang CC, Chiang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 2002;57:136-41.
14. De Schoenmakere G, Lameire N, Dhondt A, et al. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant 1998;13:1770-5.
15. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. Eur J Clin Pharmacol 1996;50:171-7.
16. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease Update 2000. Am J Kidney Dis 2001;37(suppl 1):S182-238.
17. Jacobs C, Horl WH, Macdougall IC, et al. European Best Practice Guidelines 9-13: anaemia management Nephrol Dial Transplant 2000;15(suppl4):33- 42.
18. Brimble KS, Rabbat CG, McKenna P, Lambert K, Carlisle EJ. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial. J Am Soc Nephrol 2003;14:2654-61.
19. Opatrny K Jr, Opatrna S, Sefrna F, Wirth J. The anemia in continuous ambulatory peritoneal dialysis patients is related to Kt/V index. Artif Organs 1999;23:65-9.
20. 2001 Report, volume 1. Dialysis and transplantation. Canadian Organ Replacement Register. Ottawa: Canadian Institute for Health Information, August 2001.